secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-01-12T23:59:59+00:00
Accession:  0001654954-24-000523
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics receives Nasdaq delisting notice; appoints interim CFO Lawrence Hoffman
--------------------------------------------------------------------------------

- Nasdaq notified Tenax on Jan 11, 2024 that it fails minimum 500,000 publicly held shares after 1-for-80 reverse split.
- Company has until Feb 26, 2024 to submit a compliance plan; no immediate effect on listing or trading.
- Lawrence Hoffman appointed Interim CFO effective Jan 11, 2024, succeeding Eliot Lurier (deceased).
- Hoffman will be paid $416/hour through Danforth Advisors consulting agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/0001654954-24-000523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424000523/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-000523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer